Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ultraviolet A1 phototherapy.

R S Dawe1

  • 1Photobiology Unit, Department of Dermatology, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. r.s.dawe@dundee.ac.uk

The British Journal of Dermatology
|May 20, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized assessor-blinded comparison of low-irradiance and conventional-irradiance photodynamic therapy for superficial basal cell carcinoma and Bowen disease.

The British journal of dermatology·2021
Same author

Photodiagnostic services in the UK and Republic of Ireland: a British Photodermatology Group Workshop Report.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Response to 'Decline in the use of phototherapy in France from 2010 to 2019'.

The British journal of dermatology·2021
Same author

Methotrexate combined with omalizumab for difficult to treat urticaria: a further step-up treatment?

Clinical and experimental dermatology·2020
Same author

No association between whole-body ultraviolet A1 phototherapy and skin cancers in humans: a cancer registry linkage study.

The British journal of dermatology·2020
Same author

Choice of topical prodrug in daylight photodynamic therapy for actinic keratoses.

The British journal of dermatology·2019
Same journal

Does loss of chromosome Y in blood contribute to the sex disparity of dermatitis and eczema at older ages?

The British journal of dermatology·2026
Same journal

Soluble CD83 reverses alopecia areata via IDO-mediated Treg cell activation.

The British journal of dermatology·2026
Same journal

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

The British journal of dermatology·2026
Same journal

Clinicopathological features of lymphocytic thrombophilic arteritis and the relationship with livedoid vasculopathy - a case series of 36 patients.

The British journal of dermatology·2026
Same journal

Improving Prognostication for Cutaneous Squamous Cell Carcinoma.

The British journal of dermatology·2026
Same journal

Recurrent and novel GLTP variants in five patients with nonsyndromic epidermal differentiation disorder: phenotypic and genotypic expansion.

The British journal of dermatology·2026
See all related articles

Long-wavelength ultraviolet A (UVA1) therapy shows promise for various skin conditions like atopic dermatitis and localized scleroderma. While effective for some, further research is needed to confirm UVA1 efficacy and optimal usage protocols.

Area of Science:

  • Dermatology
  • Phototherapy
  • Ultraviolet Radiation

Background:

  • Long-wavelength ultraviolet A (UVA1) therapy (340-400 nm) has been available since 1981.
  • Recent years have seen increased research into UVA1's therapeutic potential.
  • Availability is limited to specialized dermatology departments.

Purpose of the Study:

  • To review the current evidence for UVA1 therapy in various dermatological conditions.
  • To assess the efficacy and potential indications of UVA1.
  • To identify areas requiring further research.

Main Methods:

  • Review of published studies and case series on UVA1 therapy.
  • Analysis of UVA1 efficacy in different dermatological diseases.
  • Consideration of UVA1 dosage (high, medium, low) and its impact.

Related Experiment Videos

Main Results:

  • High-dose UVA1 is effective as monotherapy for acute atopic dermatitis flares.
  • UVA1 shows promise for localized scleroderma, a condition with limited treatment options.
  • Evidence suggests potential benefits for systemic lupus erythematosus, polymorphic light eruption, cutaneous T-cell lymphoma, lichen sclerosus, keloids, systemic sclerosis, and hand dermatitis.
  • Low and medium-dose UVA1 may be less effective for atopic dermatitis.

Conclusions:

  • UVA1 is a valuable addition to phototherapy options in centers where it is available.
  • Further research is essential to confirm efficacy for numerous potential indications.
  • Optimal usage protocols, including specific indications and treatment parameters, require determination.